Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Parion Sciences has presented preliminary results from a Phase I clinical safety study of a novel sodium channel blocker, P-552-02, as a topical therapy for dry mouth associated with primary Sjogren's syndrome.
Subscribe to our email newsletter
The preliminary results of the 28-day, 30-patient, randomized, double-blind, placebo-controlled, crossover study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically. No side effects or other safety issues were reported in the study.
Ross Johnson, Parion’s CEO, said: “Based on these results, we plan to proceed with a Phase I/IIA study designed to test the efficacy of higher concentrations of P-552-02 delivered in a spray formulation and dosing at different intervals, and to pursue other potential indications.”